U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07457762) titled 'AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?' on Dec. 16, 2025.
Brief Summary: Pulmonary Arterial Hypertension is a rare and progressive condition that compromises pulmonary circulation and can lead to right ventricular failure. Despite recent advances in diagnosis and treatment, the median survival of patients is only 2.8 years. The treatment for this disease is based on drugs that act on three main pathways: prostacyclin, endothelin, and nitric oxide. Iloprost, a prostacyclin analogue available in an inhaled form, is an important and well-established treatment. However, its mandatory...